UGANDA – A prevalence study conducted in Uganda ha shown that one in five people in Uganda aged 60 and above, has Alzheimer’s disease or related forms of dementia, raising…
Read MoreTag: Alzheimer’s Disease
Biogen offers free Alzheimer’s drug as Medicare payment uncertainty remains
USA – Biogen is providing its controversial and expensive new Alzheimer’s drug free of charge for some patients amid slow claim reviews by Medicare, according to sources familiar with the…
Read MoreEli Lilly to seek FDA’s approval for Alzheimer’s drug as competition for Biogens’ Aduhelm
USA – Eli Lilly and Co has announced its plans to seek U.S. approval for its experimental Alzheimer’s disease drug by year end and believes the treatment could be favored…
Read MoreBiogen provide clarity amid controversies surrounding its FDA approved drug Aduhelm
US – Aduhelm’s approval has been the subject of extensive misinformation and misunderstanding as experts believed data from the first and second phase were not as exemplary as the third…
Read MoreFDA’s approval of aduhelm drug marred by controversy following resignations by three FDA panel members
US – Aduhelm was the first of its kind drug for Alzheimer’s disease to be approved in two decades under the accelerated approval by Food & Drug Association (FDA), however,…
Read MoreAlzheimer’s disease gaining recognition as researchers and pharma companies work to find therapy
WORLD– According to World Health Organization (WHO), Alzheimer’s disease attributes to around 60-70 % cases of dementia cases globally. WHO projects that by the year 2030, 82 million cases of…
Read MoreUK based biotech start-up Kuano raises US$1.38M to venture into Artificial Intelligence-driven drug discovery
UK – Kuano, a UK-based startup that deals in Artificial Intelligence, has raised £1M in seed funding to further expedite the development of its platform for the discovery of therapeutics…
Read MoreLilly’s donanemab receives U.S. FDA’s Breakthrough Therapy designation for treatment of Alzheimer’s disease
USA – The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for donanemab, Eli Lilly and Company’s investigational antibody therapy for Alzheimer’s disease (AD). The Breakthrough Therapy…
Read MoreGE healthcare showcase their new innovations at the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) 2021 summer conference
US – GE Healthcare showcased a new molecular imaging products and solutions as well as new opportunities to expand access to radioactive tracers and other pharmaceutical imaging agents during the…
Read MoreControversy surrounding Biogen’s newly approved Alzheimer’s drug costs FDA one more panelist
USA – A third member of a key Food and Drug Administration advisory panel has resigned over the agency’s controversial decision to approve Biogen’s new Alzheimer’s drug, Aduhelm. Dr. Aaron…
Read More